Over the years, HVRI has developed over 140 vaccines and diagnostic reagent tools, significantly impacting animal health. Our landmark achievements, recognized globally, include four major veterinary achievements of the 20th century: the EIAV donkey leucocyte attenuated vaccine, the attenuated lapinized hog cholera virus vaccine, the rinderpest attenuated ovinized and caprined vaccine for cattle, and the bovine pleuropneumonia attenuated lapinized vaccine.
Furthermore, HVRI has been instrumental in addressing global health crises such as SARS and avian influenza, enhancing the management and study of animal infectious diseases and zoonoses, and reinforcing its status as a leader in veterinary science.
Founded in 1992, Weike Biotechnology has emerged as a leading high-tech enterprise, dedicated to the development, production, and distribution of advanced biological products for animal disease control and prevention. Renowned for our commitment to research and development, we produce highly effective and practical solutions that address the global needs of animal disease prevention and treatment. Our focus extends to supporting the industrialization of animal products through innovative technology and GMP production techniques, while actively promoting and applying HVRI's revolutionary research.
Our skilled team, with seventy percent holding advanced degrees, including senior and vice senior experts, and numerous master's and doctoral degree holders, is at the core of our success. These professionals are crucial in realizing HVRI's major contributions to the field, reflecting our unwavering dedication to excellence and innovation in animal health.
In 2003, Weike Biotechnology became one of the first companies to pass the GMP check for three production lines. By 2005, two more lines met GMP standards. In 2008, we completed a new facility, which gained GMP approval from the Ministry of Agriculture in 2009 for animal biological products.
Located in Harbin's Economic-Technological evelopment zone, a major trade center in Northeast China, our modern facility, costed over 100 million RMB, covers 114,000m and has a built area of 62,000m. 

It features 17 advanced, automatic production lines and includes various support facilities such as an avian influenza antigen reservoir, quality inspection labs, R&D, animal testing, specific pathogen-free (SPF) fowl care, 3-D warehousing, sewage treatment, and a power center.
In 2010,Weike Biotechnology reinforced its dedication to quality and environmental standards by obtaining ISO  9001:2008, ISO 14001:2004, and GB/T28001:2001 certifications, demonstrating our commitment to biotechnological excellence and sustainability.

In 2008, with the approval of the National Development and Reform Committee, Weike Biotechnology spearheaded the establishment of the National High-tech Industrialization Model Base for Animal Biological Products and the Harbin Biological Industry &National High-tech Industrialization Base. Building on the success of the Heilongjiang Harbin Animal Biological Product Engineering Technology R&D Center, we are now developing the National Animal Biological Product Engineering Technology R&D Center, under the guidance of the National Development and Reform Commission.
As a designated manufacturer of avian influenza vaccines and a technology support unit for the Ministry of Agriculture, Weike Biotechnology stands out as the sole domestic producer of these vaccines. Our product range spans over 40 categories, including Avian Influenza vaccines, Porcine Reproductive and Respiratory Syndrome vaccines, and others, all maintaining leading standards in both domestic and global markets.
Our "HVRI" vaccine has been recognized as "China's First-choice Brand in Veterinary Medicine Market" and "China's Most Influential Brand of Animal Husbandry". Additionally, Weike Biotechnology has been honored as one of "China's Top 10 Manufacturers of Animal Biological Products".
Weike Biotechnology's avian influenza vaccines have been crucial in the fight against avian influenza, effectively addressing immunity issues across various bird species. These vaccines are widely used not only in China but also in countries like Vietnam, Mongolia, Egypt, Indonesia, North Korea, and Nigeria.
Embracing the HVRI spirit of "United, Dedicated, Pragmatic, Innovative", and driven by a philosophy of innovation, quality, and trust, Weike Biotechnology is committed to advancing animal husbandry. We aim to become a leader in veterinary biological products globally, with a focus on animal health and safety. By championing scientific and technological strength in animal health, we invite collaboration for mutual growth and development.